PUBLISHER: Frost & Sullivan | PRODUCT CODE: 1191724
PUBLISHER: Frost & Sullivan | PRODUCT CODE: 1191724
Antibody-drug Conjugates: Technology Growth Opportunities
Disruptive Technologies and a Conducive Funding Environment are Fostering Growth
Antibody-drug conjugates (ADCs) are therapies that target cancer cells with antigen-specific antibodies and highly toxic payloads. ADCs are currently generating interest among drug developers, contract manufacturing companies, regulatory agencies, and other stakeholders. The rise in the number of drug approvals has also sparked interest in further developing this technology, with several companies developing solutions for one or more ADC components. The development of technologies is ongoing and will only increase as applications of ADCs increasingly expand into non-oncologic indications.
This study covers several new technologies for the three ADC components (antibody, linker, and payload) and highlights drugs in clinical trials that display potential. It provides an overview of key technology platforms, patents, analytical techniques, and manufacturing developments, covering the various technological advancements that may see adoption in ADC development. It also provides an overview of the stakeholder ecosystem, identifying notable mergers, acquisitions, and partnerships. A detailed account of the funding landscape has also been provided. The study also analyzes the growth drivers and restraints influencing the market and identifies the key growth opportunities emerging from the changes in this space for stakeholders and market players to leverage.
Table of Contents
Strategic Imperatives
- Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
- The Strategic Imperative 8™
- The Impact of the Top 3 Strategic Imperatives on the Antibody-drug Conjugate (ADC) Industry
- Growth Opportunities Fuel the Growth Pipeline Engine™
- Research Methodology
Scope and Segmentation
- Research Context and Scope
- Segmentation
- Growth Drivers
- Growth Restraints
Growth Opportunity Analysis
- Introduction to ADCs
- Clinical Potential of ADCs
- ADCs: FDA Approvals
- ADC Industry Trends
Technology Snapshot
- Incremental Innovations in ADCs
- ADC Challenges and Novel Solutions
- ADC Challenges and Novel Solutions (continued)
- Characteristics of ADC Linkers
- Types of Conventional ADC Linkers
- Platforms for ADC Linkers
- Platforms for ADC Linkers (continued)
- Platforms for ADC Linkers (continued)
- Platforms for adc Linkers (continued)
- ADC Linker Developments
- Platforms to Improve adc Conjugation
- Platforms to Improve adc Conjugation (continued)
- Platforms to Improve adc Conjugation (continued)
- Characteristics of a Suitable Antibody for ADCs
- Platforms for ADC Antibodies
- Platforms for ADC Antibodies (continued)
- Antibody Developments for ADC
- Characteristics of a Suitable Cytotoxic Payload for an ADC
- Platforms for Cytotoxic Payload for an ADC
- Platforms for Cytotoxic Payload for an ADC (continued)
- Payload Developments for ADCs
- Novel Platforms for ADC Delivery
Manufacturing, Analytical Techniques, and Other Factors
- Impact on CDMOs
- ADC: Analysis Technologies, Challenges, and New Developments
- ADC: Clinical Pipeline
Stakeholder Ecosystem
- M&As
- Partnerships and Collaborations for ADCs
- Partnerships and Collaborations for ADCs (continued)
- Partnerships and Collaborations for ADCs (continued)
- Technology Licensing Deals for ADC Development
Funding Landscape
- Funding Analysis
- Funding Analysis (continued)
- Funding Analysis (continued)
Growth Opportunity Universe
- Growth Opportunity 1: Non-oncological Indications
- Growth Opportunity 1: Non-oncological Indications (continued)
- Growth Opportunity 2: Manufacturing and Supply Chain
- Growth Opportunity 2: Manufacturing and Supply Chain (continued)
- Growth Opportunity 3: Advancements in Linker Chemistry and Antibodies
- Growth Opportunity 3: Advancements in Linker Chemistry and Antibodies (continued)
Next Steps
- Your Next Steps
- Why Frost, Why Now?
- Legal Disclaimer
